Abbott Gets CE Mark for Libre Duo Dual Glucose and Ketone Monitor

Abbott Laboratories (NYSE:ABT) secured European CE Mark approval for Libre Duo, described as the world's first dual glucose and ketone continuous monitoring sensor. The company presented new data at the American Diabetes Association's 2026 Scientific Sessions on diabetic ketoacidosis risk and outcomes from its Healthy Food Rx program for people with type 2 diabetes. The American Cancer Society reaffirmed Abbott's Cologuard and Cologuard Plus as preferred options in updated US colorectal cancer screening guidelines.

The Product

Libre Duo continuously monitors both glucose and ketone levels, helping diabetes patients avoid diabetic ketoacidosis, a dangerous condition that can lead to coma or death. The device received CE Mark, allowing marketing in the European Union.

Pricing and Availability

Abbott has not yet disclosed pricing or launch timeline for Libre Duo in European markets. Additional details are expected in the coming months.

Competition

Abbott faces competition in the continuous glucose monitoring market from Dexcom and Medtronic. However, Libre Duo is the first to combine glucose and ketone monitoring in a single sensor, potentially giving it a competitive edge.

Potential Impact on the Company

The Libre Duo launch could strengthen Abbott's position in the diabetes monitoring market and support revenue growth in its healthcare segment. The American Cancer Society's reaffirmation of Cologuard also boosts investor confidence in Abbott's cancer screening products.